reports
Columbus Interim Report Q1 2025
Columbus Interim Report Q1 2025 Company announcement no. 5/2025 Solid operational performance in Q1 2025 Columbus delivered a solid start to 2025, driven by improved earnings, confirming the robustness of the strategy and business model. Despite a slight decline in revenue of 2%, a 32% improvement in EBITDA was achieved, significantly strengthening profitability and increasing the EBITDA margin to 10.7% compared to 7.9% in Q1 2024, adjusted for the extraordinary gain of DKK 20m from the M3CS legal case. Overall, a satisfactory start to the year. “Despite global uncertainty, Q1 2025 refle...
- Patrik Ling
Arjo (Hold, TP: SEK35.00) - Soft start to 2025
Q1 sales were broadly in line, but adj. EBITDA was c8% below our forecast and c6% below consensus. The main differences came from higher operating expenses than expected as well as a slightly lower gross margin. Product sales were weak, but service/spare parts and rental saw stronger sales than expected, a mix that is generally negative for the margin trend. We reiterate our HOLD and have cut our target price to SEK35 (42).
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Passing of Columbus A/S’ Annual General Meeting and subsequent constit...
Passing of Columbus A/S’ Annual General Meeting and subsequent constitution of the Board of Directors Company announcement no. 4/2025 At Columbus A/S’ Annual General Meeting held on 29 April 2025, all proposals set out in the agenda were adopted, including the following; 1. The General Meeting took note of the Board of Directors’ report. 2. The Annual Report for 2024 was approved. 3. The Board of Directors’ proposal regarding distribution of profit was adopted, including payment of an ordinary dividend to the shareholders of DKK 0.125 per share of DKK 1.25 (nom), amounting to a total ...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Q1 revenue beats, but FX-driven EBIT miss masks solid mom...
BONESUPPORT reported a robust Q1, with net sales of SEK283.5m beating CSS SEK276m and driven by CERAMENT G sales of SEK178m in North America — well ahead of the SEK160m forecast. Gross margin remained best-in-class at 92.6%, slightly above expectations, underscoring the strength of the business mod
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Model Update – Reiterate BUY and SEK400 PT
We have updated our model, rolling it over after Q4 results and in preparation for Q1 2025, to be reported on 24 April. While our long-term conviction for BONESUPPORT products has not changed, we have slightly softened our 2025 EU sales growth assumptions from 39% to 22% YoY growth following a slow
- ABGSC Healthcare Research
- Sten Gustafsson
Indkaldelse til ordinær generalforsamling
Indkaldelse til ordinær generalforsamling Selskabsmeddelelse nr. 3/2025 I henhold til vedtægternes pkt. 9.1 indkaldes til ordinær generalforsamling i Columbus A/S: Tirsdag den 29. april 2025 kl. 10.00 hos Columbus, Lautrupvang 6, 2750 Ballerup Dagsorden: 1. Bestyrelsens beretning om selskabets virksomhed i det forløbne år. 2. Forelæggelse og godkendelse af årsrapport. 3. Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport. 4. Præsentation af og vejledende afstemning om vederlagsrapport. 5. Forslag om bemyndigelse af bestyrelsen ti...
Notice to convene Annual General Meeting
Notice to convene Annual General Meeting Company announcement no. 3/2025 According to Art. 9.1 of the Articles of Association, notice is hereby given of the Annual General Meeting of Columbus A/S to be held on: Tuesday 29 April 2025 at 10.00 at Columbus, Lautrupvang 6, 2750 Ballerup Agenda: 1. Board of Directors’ report on the business of the Company during the past year. 2. Presentation and approval of the Annual Report. 3. Resolution on the appropriation of profit or covering of loss as recorded in the adopted Annual Report. 4. Presentation of and indicative ballot on the Remuner...
- Patrik Ling
Arjo (Hold, TP: SEK42.00) - Stable Q1 expected
We are slightly below consensus for Q1, but believe this is due to different FX assumptions and our inclusion of higher one-off costs. We see stable sales and improving growth in 2025, with a new CEO not expected until H2. We reiterate our HOLD, but have trimmed our target price to SEK42 (43) following our forecast adjustments.
Annual Report 2024
Annual Report 2024 Company announcement no. 2/2025 2024 financial performance: Continued growth and solid EBITDA margin Columbus’ revenue amounted to DKK 1,659m in 2024, corresponding to an increase of 8%. Organically, revenue grew by 7%. EBITDA increased by 30% to DKK 153m. Most of our global Business Lines have been performing well in 2024, with our largest business, Dynamics, delivering 11% growth. The M3 business is back to growth delivering 6% growth, while Data & AI is capitalizing on the emerging technological trends, delivering 15% growth. Our CXE business continues to per...
- ABGSC Small Cap Research
- Karl Bokvist
- Nikola Kalanoski
- Simon Jönsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Closing a solid 2024
2024 saw BONESUPPORT further accelerate its market leadership with Q4 sales reaching SEK257m—up 49% YoY—driving FY sales to SEK898.7m (52% YoY), in line with guidance of 50% topline growth. In North America, CERAMENT G continued its strong performance, rising by approximately SEK22m QoQ to reach ar
- ABGSC Healthcare Research
- Sten Gustafsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.